Dr. Jingfu Wang 王景福
Chief Physician
Pediatric Oncology, Cancer Hospital of Shandong First Medical University (Shandong Cancer Hospital), Jinan
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Surgical, chemotherapy, radiotherapy, immunotherapy, and stem cell transplantation for pediatric solid tumors.
Dr. Wang holds a PhD in Oncology from Tianjin Medical University (2011). After training at Osaka University Hospital (2009–2010), Dr. Wang worked at Tianjin Children's Hospital and Tianjin Medical University Cancer Institute. Clinical experience includes comprehensive treatment of pediatric solid tumors, such as neuroblastoma, Wilms tumor, hepatoblastoma, germ cell tumors, soft tissue tumors, and lymphoma.
Professional roles
- Young Council Member, China Anti-Cancer Association
- Vice Chair, Pediatric Oncology Youth Professional Committee, China Anti-Cancer Association
- Member, Tianjin Pediatric Oncology Professional Committee, China Anti-Cancer Association
Name order: in Chinese the family name comes first (Wang Jingfu). Papers usually list the name as Jingfu Wang or Wang J.
Selected publications
14 papers on PubMed matched by name and affiliation; 4 as first or senior author since 2016. Most recent first- or senior-author papers:
- Pediatr Blood Cancer, 2026 (senior author): Local Control Efficacy of Radiotherapy and Prognostic Factors in Pancreatoblastoma: A Single-Center Experience With a Rare Pediatric Tumor. PubMed 41560590
- Oncol Lett, 2026 (senior author): Extended cycles of anti-GD2 antibody dinutuximab beta treatment combined with chemotherapy in patients with relapsed or refractory neuroblastoma: A retrospective study. PubMed 41480118
- AME Case Rep, 2025 (senior author): Clinical insights from the management of a giant immature teratoma in an infant-a case report. PubMed 40761204
- BMC Pediatr, 2025 (senior author): A clinical observational study of dinutuximab beta as first-line maintenance treatment for patients with high-risk neuroblastoma in China. PubMed 40091019
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion